A Phase I Clinical Trial of BAT4406F Injection in Patients With Neuromyelitis Optica Spectrum Disorders
Status:
Not yet recruiting
Trial end date:
2021-12-01
Target enrollment:
Participant gender:
Summary
This study is a phase I clinical study of the safety, tolerability, and pharmacokinetics of
BAT4406F injection in patients with neuromyelitis optica spectrum disorders.